Rejuvenate Bio — Gene Therapy Platform
$130M+ in disclosed contracted development and milestone payments
Opportunity teaser
Gene-therapy company developing one-time treatments for age-related, metabolic and cardiovascular decline across animal and human health.
Why it may be interesting
Strategic animal-health partnerships, non-dilutive funding, a disclosed $6M institutional round and a dual human/animal platform support a significant life-sciences thesis.
Risks and open questions
This is a high-risk biotechnology investment. Validate preclinical evidence, human-trial readiness, milestone contingencies, licensing rights, manufacturing scalability, cash runway, regulatory pathways, dilution and forward revenue claims.
Key figures
- Stage
- Growth / Community Round
- Target raise
- —
- Sector
- Biotechnology / Gene Therapy
- Headquarters
- —
- Issuer
- Rejuvenate Bio
- Selected traction
- as of2026-07-25securityPreferred Stockshare price0.91raised snapshot8475338investors snapshot846+pre money valuation59400000non dilutive funding claim$13M+contracted milestones claim$130M+cumulative partner value claim$5.1M
Eligibility notice
This is a third-party securities offering hosted by Wefunder Portal LLC. Eligibility, investment limits, terms and availability are determined by the platform and applicable law. Biotechnology investments are speculative, illiquid and exposed to clinical, regulatory and financing failure, including total loss.
Disclosure
Informational summary of a third-party securities offering. Merge & Acquire is not the issuer, funding portal, broker-dealer or investment adviser and does not recommend or solicit an investment. Review the Form C, stock documents and Wefunder disclosures before investing.